Answering the question post #3 raises rather than the one it answers. Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be clinically unimportant, which is not true of every injectable.
The question in the title: What the published dose-response for semaglutide actually looks like above 2.4 mg I will give what I have already checked below so nobody repeats it.
I would like to know what people here actually do about published dose-response for semaglutide, as distinct from what is usually recommended. Those have diverged in every other subject I have looked at closely.
Mine is below, with the reasoning, including the parts I am not confident about.
Taking the opening post at face value and following it one step further.
Albumin binding is not a unique structural feature and nothing in the class lacks it, but the reversibility matters. Semaglutide binds albumin covalently through a fatty side chain, which creates a very long half-life at the cost of sequestering the free form. That is a trade-off and it is the trade-off that allows weekly dosing.
Approved indications differ by jurisdiction and change. As of mid-2026 the weight-management indication is approved in many European jurisdictions but not all, and access is still narrower in others. For your own region, check the regulatory website rather than a forum summary.
Noting that I have skin in this question and have tried to discount for it.
The failure mode on published dose-response for semaglutide is boring rather than dramatic. It is almost always the step everyone assumes was done correctly because it is too simple to get wrong.
The most useful reply I ever got about published dose-response for semaglutide was a request to state my units. It sounds like pedantry and it has saved me twice.
Building on post #3 rather than restating it.
The STEP programme populations were selected: enrollment criteria required baseline body mass index over 30, no recent blood pressure crisis, no recent retinopathy, no renal disease at the time. Applying results from that population to someone well outside it is an extrapolation and should be called one.
Answering the question post #3 raises rather than the one it answers.
Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be clinically unimportant, which is not true of every injectable.
Solutions of semaglutide can look faintly opalescent without anything being wrong. Visible particulate, fibres or frank cloudiness are a different observation entirely and are worth raising with the supplier rather than reasoning about.
One more caveat and then I will stop qualifying: the sample selected itself.
Useful. I had the fact and not the reason, which turns out to be the important half.
Post #10 and I disagree about the size of the effect, not about the direction.
On published dose-response for semaglutide, the part that usually goes wrong is that the question is asked as though it has one answer. It has a range, and the width of the range is the interesting bit.
If you can post the two or three numbers you are working from, several people here will check the arithmetic rather than argue about the conclusion.
Narrowing post #12, because the general version has more than one answer.
On dose steps: the four-week interval in the pivotal programme was a trial design choice, and slower escalation was not studied. That means the evidence supports not going faster and says nothing at all about going slower.
Taking post #12 at face value and following it one step further.
Where the published dose-response for semaglutide reasoning breaks down for me is the step from the group result to the individual case. That step is almost never argued for.
The opalescent appearance in semaglutide solutions is occasionally noted and the mechanism is unclear. It does not appear to correlate with product failure in practice. Visible particles or frank cloudiness is different and would be reason to contact the supplier.
On alcohol: the labelling does not contraindicate it, but it raises gastric irritation risk and semaglutide already does that. There is no published interaction study and the conservative position is to limit it if you are titrating or if gastrointestinal symptoms are troublesome.
Posting it because the silence on this was starting to look like agreement.
Source for the published dose-response for semaglutide figure, since it was asked for. It is in the discussion rather than the abstract, which is why the version circulating is stronger than the paper is.
Reading the surrounding paragraph is worth the two minutes. The authors are more careful than their summarisers.
Where I part company with post #19, and it is a narrow parting.
Renal outcomes moved this compound out of the metabolic-only conversation. FLOW reported on kidney endpoints in people with type 2 diabetes and chronic kidney disease, which is a narrower population than the discussion here usually assumes.
Genuinely open to being wrong about this one.
Adding the measurement that post #23 says would settle it.
On the injection-day question: the labelling for licensed semaglutide allows the day to be changed provided at least two days separate the two injections. That interval is not arbitrary — it is what stops two doses stacking inside one absorption window.
The part I am sure of is shorter than the part I have written.
On identity confirmation: a mass close to 4113.6 Da on the intact molecule is consistent with semaglutide and is also consistent with several closely related species. Mass narrows the field; it does not close it, and no certificate should be read as though it did.
If that is already documented somewhere, ignore me and link it.
I have no financial interest in anything named in this thread and I want to say so before I comment on published dose-response for semaglutide, because it is the sort of subject where it matters.
On post #23 — agreed on the reasoning, with one qualification.
The version of published dose-response for semaglutide that circulates here is a simplification of a simplification. It is not wrong, but it has lost the conditions under which it holds, and those conditions are where the interesting cases live.
Picking up post #27: that is the part I would want checked first.
Is there a ceiling dose beyond which the effect plateaus? The trials did not study that because they stopped at 2.4 mg. Some people report trying higher doses, but trial data is absent and off-label dosing enters territory this site does not advise on.
The strength of my opinion here exceeds the strength of my evidence.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Why semaglutide solutions can look faintly opalescent and when that matters
The question in the title: Why semaglutide solutions can look faintly opalescent and when that matters I will give what I have already checked below so nobody repeats it. A follow-up question about…
|
+73 | 79 | 2k | 4mo |
|
Revisiting: Is there a ceiling dose beyond which semaglutide stops adding benefit?
Revisiting: Is there a ceiling dose beyond which semaglutide stops adding benefit? — that is the question, and I have not found it answered plainly anywhere I have looked. Putting the numbers in the first…
|
+5 | 9 | 30k | 8d |
|
Semaglutide in people without diabetes: what the evidence base looks like
Semaglutide in people without diabetes: what the evidence base looks like Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of semaglutide…
|
+2 | 6 | 18k | 17mo |
|
What SELECT changed about how semaglutide is discussed, and what it did not
Asking directly, because I could not find a straight answer: What SELECT changed about how semaglutide is discussed, and what it did not I was wrong about SELECT in a thread last spring and I would like to…
|
+120 | 132 | 2k | 14mo |
|
Semaglutide half-life: where the 165 to 184 hour figure comes from
Semaglutide half-life: where the 165 to 184 hour figure comes from — setting out what I have, and where I think it stops being reliable. Putting the numbers in the first post, because a question about a…
|
+128 | 145 | 3k | 4mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
A 40-week log with the measurement method stated — does this still hold?
A 40-week log with the measurement method stated — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Posting a small dataset on 40-week log. It is…
|
+1 | 5 | 14k | 2mo |
|
Stepping down deliberately, and how to do it without losing progress — what changed since
Posting this under the heading it deserves: Stepping down deliberately, and how to do it without losing progress — what changed since Everything below is what sits behind that. Something changed and I would…
|
+94 | 99 | 29k | 2d |
|
The most common factual error about semaglutide on the internet — what changed since
The most common factual error about semaglutide on the internet — what changed since — setting out what I have, and where I think it stops being reliable. Putting the numbers in the first post, because a…
|
+42 | 46 | 1.7k | 5mo |
|
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile
Posting this under the heading it deserves: Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile Everything below is what sits behind that. Semaglutide and gastric emptying,…
|
+115 | 122 | 2.6k | 1d |
|
Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one
Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one I have a specific reason for asking rather than idle curiosity, and the context is below. A methods question rather than a…
|
+130 | 135 | 11k | 7mo |